Chip Roy and Bipartisan Allies Demand Vote on Congressional Stock Trading Ban

Congressman Chip Roy and bipartisan allies are pushing for a vote on the Restore Trust in Congress Act, which would ban lawmakers, their families, and trustees from owning or trading individual stocks, securities, and other assets. The bill has 82 cosponsors, with 64 Democrats and 18 Republicans. The measure would require lawmakers to unload covered investments within 180 days and new members to divest within 90 days of taking office.

Spero Therapeutics Inc. (SPRO) saw its stock surge following the announcement of strong Phase 3 results for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections (cUTIs). The company's stock closed at $2.29, up 3.62% Spero Therapeutics, Inc. (SPRO) Stock: Surges on Positive Phase 3 Results for Oral cUTI Treatment^[1].

The pivotal Phase 3 PIVOT-PO trial demonstrated that tebipenem HBr was non-inferior to intravenous imipenem-cilastatin in treating cUTIs, including pyelonephritis. The overall success rate reached 58.5% for tebipenem HBr compared to 60.2% for the IV comparator. The study’s early termination for efficacy highlighted its strong clinical performance, and the safety profile of tebipenem HBr matched expectations with only mild or moderate adverse events observed Spero Therapeutics, Inc. (SPRO) Stock: Surges on Positive Phase 3 Results for Oral cUTI Treatment^[1].

The positive clinical outcome strengthened SPRO's position as a key player in the anti-infectives market. The company confirmed its plans to advance tebipenem HBr toward FDA submission by Q4 2025, alongside GSK plc. This development reinforces SPRO’s commitment to addressing antimicrobial resistance with novel, patient-friendly therapies Spero Therapeutics, Inc. (SPRO) Stock: Surges on Positive Phase 3 Results for Oral cUTI Treatment^[1].

The announcement significantly boosted SPRO stock momentum as traders responded to the company’s pivotal milestone. Tebipenem HBr’s success positions SPRO as a frontrunner in the race to develop the first oral carbapenem in the United States, which would mark a key step in reducing hospital stays and improving access to effective treatments Spero Therapeutics, Inc. (SPRO) Stock: Surges on Positive Phase 3 Results for Oral cUTI Treatment^[1].

The bill, which has 82 cosponsors, with 64 Democrats and 18 Republicans, would ban lawmakers, their families, and trustees from owning or trading individual stocks, securities, and other assets. The measure would require lawmakers to unload covered investments within 180 days and new members to divest within 90 days of taking office .